Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Glynn, George Schreiber, M. Busch, S. Kleinman, Alan Williams, C. Nass, H. Ownby, J. Smith (1998)
Demographic characteristics, unreported risk behaviors, and the prevalence and incidence of viral infections: a comparison of apheresis and whole‐blood donors. The Retrovirus Epidemiology Donor StudyTransfusion, 38
G. Schreiber, M. Busch, S. Kleinman, J. Korelitz (1996)
The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.The New England journal of medicine, 334 26
R. Janssen, G. Satten, S. Stramer, B. Rawal, T. O'Brien, B. Weiblen, F. Hecht, N. Jack, F. Cleghorn, J. Kahn, M. Chesney, M. Busch (1998)
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.JAMA, 280 1
C. Schüttler, G. Caspari, C. Jursch, W. Willems, W. Gerlich, S. Schaefer (2000)
Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNAThe Lancet, 355
J. McCullough (2000)
TRANSFUSION in the New YearTransfusion, 40
J. AuBuchon, J. Birkmeyer, M. Busch (1997)
Safety of the Blood Supply in the United States: Opportunities and ControversiesAnnals of Internal Medicine, 127
G. Schreiber, M. Busch, S. Kleinman, J. Korelitz (1996)
The Risk of Transfusion-Transmitted Viral InfectionsThe New England Journal of Medicine, 334
(1999)
Resolution testing of HTLV I/II screening test repeatedly reactive donor samples by the use of a dual EIA algorithm (abstract)
R. Dodd (2002)
Germs, Gels and Genomes. A Personal Recollection of 30 Years in Blood Safety Testing
S. Glynn, S. Kleinman, G. Schreiber, M. Busch, D. Wright, James Smith, C. Nass, A. Williams (2000)
Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996.JAMA, 284
S. Stramer, S. Caglioti, D. Strong (2000)
NAT of the United States and Canadian blood supplyTransfusion, 40
Ai Ling, K. Robbins, Teresa Brown, Valerie Dunmire, S. Thoe, Sin-Yew Wong, Yee Leo, Diana Teo, James Gallarda, Bruce Phelps, Mary Chamberland, Michael Busch, T. Folks, Marcia Kalish (2000)
Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period.JAMA, 284 2
J. Korelitz, M. Busch, S. Kleinman, A.E. Williams, R. Gilcher, H. Ownby, G. Schreiber (1997)
A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor StudyTransfusion, 37
R. Dodd, S. Stramer, J. Aberle‐grasse, E. Notari (2000)
Risk of hepatitis and retroviral infections among blood donors and introduction of nucleic acid testing (NAT).Developments in biologicals, 102
(2000)
The yield of nucleic acid testing ( NAT ) for HIV and HCV RNA in a population of U . S . voluntary donors : relationship to contemporary measures of incidence ( abstract )
M. Goldman (1999)
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
S. Glynn, S. Kleinman, G. Schreiber, M. Busch, D. Wright, J. Smith, C. Nass, A. Williams (2000)
Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS)JAMA, 284 2
(2002)
A method for DODD ET AL
BACKGROUND : There has been continuing prog‐ ress in measures to reduce the risk of transfusion‐ transmitted infection, including introduction of serologic tests of increased sensitivity and the recent implementation of investigational NAT in small pools of samples. STUDY DESIGN AND METHODS : Data relating to all blood donations to the American Red Cross have been consolidated into a single database. The prevalence of confirmed‐positive test results for HBsAg, HCV, HIV, and HTLV were evaluated for each year for first‐time donors from 1995 through 2001. Incidence rates for these infections were evaluated among repeat donors having at least two donations in a 2‐year period. The frequencies of HIV‐1 RNA‐ and HCV RNA‐positive, seronegative donations were assessed for first‐time and repeat donations. The relationship risk = (window period) × (incidence) was used to assess residual risk among repeat donations and to evaluate the incidence of HCV and HIV infection among first‐time donors. RESULTS : During the study period, prevalence rates for all markers declined significantly over time: in 2001, the rates per 100,000 were 75.6 for HBsAg, 299 for HCV, 9.7 for HIV, and 9.6 for HTLV; the corresponding incidence rates (/100,000 person‐years) were 1.267, 1.889, 1.554, and 0.239, respectively. Estimates of residual risk in donations from repeat donors (after NAT) for HCV and HIV were 1 per 1,935,000 and 1 per 2,135,000, respectively. However, incidence rates for these agents are approximately two times greater among first‐time donors. For both HCV and HIV, NAT yield was concordant with that predicted by current window‐period models. CONCLUSION : These data cover about half of all the whole blood collected in the United States. They suggest increasing improvement in transfusion safety and clearly define the benefit of pooled NAT.
Transfusion – Wiley
Published: Aug 1, 2002
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.